James J. Vredenburgh

21.0k total citations · 6 hit papers
266 papers, 15.2k citations indexed

About

James J. Vredenburgh is a scholar working on Genetics, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, James J. Vredenburgh has authored 266 papers receiving a total of 15.2k indexed citations (citations by other indexed papers that have themselves been cited), including 144 papers in Genetics, 103 papers in Oncology and 93 papers in Pulmonary and Respiratory Medicine. Recurrent topics in James J. Vredenburgh's work include Glioma Diagnosis and Treatment (132 papers), Brain Metastases and Treatment (57 papers) and Cancer Treatment and Pharmacology (43 papers). James J. Vredenburgh is often cited by papers focused on Glioma Diagnosis and Treatment (132 papers), Brain Metastases and Treatment (57 papers) and Cancer Treatment and Pharmacology (43 papers). James J. Vredenburgh collaborates with scholars based in United States, Thailand and Canada. James J. Vredenburgh's co-authors include Henry S. Friedman, David A. Reardon, Annick Desjardins, James E. Herndon, Allan H. Friedman, Jeremy N. Rich, John H. Sampson, Darell D. Bigner, Jennifer A. Quinn and Roger E. McLendon and has published in prestigious journals such as Nature, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

James J. Vredenburgh

260 papers receiving 14.9k citations

Hit Papers

Bevacizumab Alone and in ... 2003 2026 2010 2018 2009 2007 2007 2010 2003 500 1000 1.5k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Bevacizumab Alone and in Combination With Irinotecan in Recurrent Glioblastoma
    2009 1.9k citations Henry S. Friedman, Michael D. Prados et al. Journal of Clinical Oncology profile →
  2. Bevacizumab Plus Irinotecan in Recurrent Glioblastoma Multiforme
    2007 1.0k citations James J. Vredenburgh, Annick Desjardins et al. Journal of Clinical Oncology profile →
  3. Phase II Trial of Bevacizumab and Irinotecan in Recurrent Malignant Glioma
    2007 815 citations James J. Vredenburgh, Annick Desjardins et al. Clinical Cancer Research profile →
  4. Immunologic Escape After Prolonged Progression-Free Survival With Epidermal Growth Factor Receptor Variant III Peptide Vaccination in Patients With Newly Diagnosed Glioblastoma
    2010 613 citations John H. Sampson, Amy B. Heimberger et al. Journal of Clinical Oncology profile →
  5. Phase II Trial of Gefitinib in Recurrent Glioblastoma
    2003 558 citations Jeremy N. Rich, David A. Reardon et al. Journal of Clinical Oncology profile →
  6. Tetanus toxoid and CCL3 improve dendritic cell vaccines in mice and glioblastoma patients
    2015 410 citations Duane A. Mitchell, Smita K. Nair et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
James J. Vredenburgh United States 63 8.2k 4.7k 4.1k 3.6k 3.4k 266 15.2k
Anas Younes United States 77 5.0k 0.6× 10.9k 2.3× 6.5k 1.6× 2.7k 0.8× 2.0k 0.6× 529 22.1k
David Schiff United States 69 8.0k 1.0× 2.8k 0.6× 4.5k 1.1× 3.8k 1.1× 3.0k 0.9× 373 16.9k
W.K. Alfred Yung United States 64 6.4k 0.8× 3.8k 0.8× 8.1k 2.0× 2.9k 0.8× 3.2k 0.9× 175 15.0k
Joachim Yahalom United States 65 3.8k 0.5× 4.9k 1.0× 1.7k 0.4× 2.7k 0.7× 1.4k 0.4× 272 14.5k
Apostolia M. Tsimberidou United States 58 2.5k 0.3× 5.4k 1.2× 4.8k 1.2× 3.3k 0.9× 4.2k 1.2× 445 14.5k
James M. Boyett United States 70 7.8k 0.9× 2.2k 0.5× 4.4k 1.1× 2.9k 0.8× 913 0.3× 232 15.2k
Vittorina Zagonel Italy 52 2.3k 0.3× 5.3k 1.1× 2.0k 0.5× 2.4k 0.7× 1.4k 0.4× 467 11.4k
Olivier Chinot France 52 7.5k 0.9× 2.2k 0.5× 3.1k 0.7× 3.3k 0.9× 2.4k 0.7× 296 11.7k
Lauren E. Abrey United States 70 12.0k 1.5× 3.3k 0.7× 2.8k 0.7× 4.8k 1.3× 2.3k 0.7× 236 17.6k
Dan G. Duda United States 64 2.7k 0.3× 7.7k 1.6× 8.2k 2.0× 3.3k 0.9× 4.6k 1.4× 230 19.3k

Countries citing papers authored by James J. Vredenburgh

Since Specialization
Citations

This map shows the geographic impact of James J. Vredenburgh's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by James J. Vredenburgh with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites James J. Vredenburgh more than expected).

Fields of papers citing papers by James J. Vredenburgh

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by James J. Vredenburgh. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by James J. Vredenburgh. The network helps show where James J. Vredenburgh may publish in the future.

Co-authorship network of co-authors of James J. Vredenburgh

This figure shows the co-authorship network connecting the top 25 collaborators of James J. Vredenburgh. A scholar is included among the top collaborators of James J. Vredenburgh based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with James J. Vredenburgh. James J. Vredenburgh is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Ozcan, Gonca, et al.. (2022). Leptomeningeal Metastasis from Non–Small Cell Lung Cancer and Current Landscape of Treatments. Clinical Cancer Research. 29(1). 11–29. 63 indexed citations
2.
Thomas, Vinay Mathew, et al.. (2021). Lung adenocarcinoma with metastasis to the vitreous – A case report and review of literature. SHILAP Revista de lepidopterología. 3. 100064–100064. 2 indexed citations
3.
Mar, Nataliya & James J. Vredenburgh. (2015). Dual HER2 Blockade in Non-Small Cell Lung Cancer Harboring a HER2 Mutation.. PubMed. 79(9). 531–5. 2 indexed citations
4.
Sampson, John H., Robert J. Schmittling, Gary E. Archer, et al.. (2012). A Pilot Study of IL-2Rα Blockade during Lymphopenia Depletes Regulatory T-cells and Correlates with Enhanced Immunity in Patients with Glioblastoma. PLoS ONE. 7(2). e31046–e31046. 91 indexed citations
5.
Reardon, David A., April Coan, James E. Herndon, et al.. (2011). Exercise Behavior, Functional Capacity, and Survival in Adults With Malignant Recurrent Glioma. Journal of Clinical Oncology. 29(21). 2918–2923. 94 indexed citations
6.
Vredenburgh, James J., Annick Desjardins, David A. Reardon, et al.. (2011). The Addition of Bevacizumab to Standard Radiation Therapy and Temozolomide Followed by Bevacizumab, Temozolomide, and Irinotecan for Newly Diagnosed Glioblastoma. Clinical Cancer Research. 17(12). 4119–4124. 112 indexed citations
7.
Reardon, David A., Annick Desjardins, Katherine B. Peters, et al.. (2011). Phase 2 study of carboplatin, irinotecan, and bevacizumab for recurrent glioblastoma after progression on bevacizumab therapy. Cancer. 117(23). 5351–5358. 69 indexed citations
8.
Sampson, John H., Amy B. Heimberger, Gary E. Archer, et al.. (2010). Immunologic Escape After Prolonged Progression-Free Survival With Epidermal Growth Factor Receptor Variant III Peptide Vaccination in Patients With Newly Diagnosed Glioblastoma. Journal of Clinical Oncology. 28(31). 4722–4729. 613 indexed citations breakdown →
9.
Peters, Katherine B., Roger E. McLendon, Michael A. Morse, & James J. Vredenburgh. (2010). Treatment of Recurrent Intracranial Hemangiopericytoma with SRC-Related Tyrosine Kinase Targeted Therapy: A Case Report. Case Reports in Oncology. 3(1). 93–97. 23 indexed citations
10.
Friedman, Henry S., Michael D. Prados, Patrick Y. Wen, et al.. (2009). Bevacizumab Alone and in Combination With Irinotecan in Recurrent Glioblastoma. Journal of Clinical Oncology. 27(28). 4733–4740. 1855 indexed citations breakdown →
11.
Desjardins, Annick, David A. Reardon, James E. Herndon, et al.. (2008). Bevacizumab Plus Irinotecan in Recurrent WHO Grade 3 Malignant Gliomas. Clinical Cancer Research. 14(21). 7068–7073. 130 indexed citations
12.
Sathornsumetee, Sith, David A. Reardon, Annick Desjardins, et al.. (2007). Molecularly targeted therapy for malignant glioma. Cancer. 110(1). 13–24. 250 indexed citations
13.
Nieto, Yago, James J. Vredenburgh, Elizabeth J. Shpall, et al.. (2004). Phase II Feasibility and Pharmacokinetic Study of Concurrent Administration of Trastuzumab and High-Dose Chemotherapy in Advanced HER2+ Breast Cancer. Clinical Cancer Research. 10(21). 7136–7143. 12 indexed citations
14.
Petros, William P., et al.. (2000). Pulmonary Toxicity of Induction Chemotherapy Prior to Standard or High-dose Chemotherapy with Autologous Hematopoietic Support. American Journal of Respiratory and Critical Care Medicine. 161(1). 17–25. 60 indexed citations
15.
Selzner, Markus, Michael A. Morse, James J. Vredenburgh, William C. Meyers, & Pierre–Alain Clavien. (2000). Liver metastases from breast cancer: Long-term survival after curative resection☆. Surgery. 127(4). 383–389. 162 indexed citations
16.
Morse, Michael A., James J. Vredenburgh, & H. Kim Lyerly. (1999). A Comparative Study of the Generation of Dendritic Cells from Mobilized Peripheral Blood Progenitor Cells of Patients Undergoing High-Dose Chemotherapy. Journal of Hematotherapy & Stem Cell Research. 8(6). 577–584. 21 indexed citations
17.
Erasmus, Jeremy J., et al.. (1998). Delayed Pulmonary Toxicity Syndrome following High-dose Chemotherapy and Bone Marrow Transplantation for Breast Cancer. American Journal of Respiratory and Critical Care Medicine. 157(2). 565–573. 78 indexed citations
18.
19.
Cohen, Andrea J., Barbara Waters‐Pick, David Coniglio, et al.. (1996). The Significance of Microbial Cultures of the Hematopoietic Support for Patients Receiving High-Dose Chemotherapy. Journal of Hematotherapy. 5(3). 289–294. 16 indexed citations
20.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Anas Younes Breakdown of academic impact, for papers by David Schiff Breakdown of academic impact, for papers by W.K. Alfred Yung Breakdown of academic impact, for papers by Joachim Yahalom Breakdown of academic impact, for papers by Apostolia M. Tsimberidou Breakdown of academic impact, for papers by James M. Boyett Breakdown of academic impact, for papers by Vittorina Zagonel Breakdown of academic impact, for papers by Olivier Chinot Breakdown of academic impact, for papers by Lauren E. Abrey Breakdown of academic impact, for papers by Dan G. Duda
Rankless by CCL
2026